Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 6
Submit an article Journal homepage
438
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas

Joseph RoswarskiCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA; ;Walter Reed National Military Medical Center, Bethesda, MD, USA; ORCID Iconhttp://orcid.org/0000-0002-1470-8814
ORCID Icon,
Mark RoschewskiCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;
,
Andrea LucasCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;
,
Christopher MelaniCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;
,
Stefania PittalugaLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
,
Elaine S. JaffeLaboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
,
Seth M. SteinbergCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;
,
Thomas A. WaldmannCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA;
&
Wyndham H. WilsonCenter for Cancer Research, National Cancer Institute, Bethesda, MD, USA; Correspondence[email protected]
 show all
Pages 1466-1469 | Received 11 Jul 2017, Accepted 26 Sep 2017, Published online: 16 Oct 2017

References

  • Coiffier B, Brousse N, Peuchmaur M, et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol. 1990;1:45–50.
  • Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25:2211–2217.
  • Pfreundschuh M, Kuhnt E, Trumper L, MabThera International Trial G, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–1022.
  • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
  • O’Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res. 2009;15:2514–2522.
  • Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717–2724.
  • Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on L, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–2323.
  • Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151:159–166.
  • Kim SJ, Yoon DH, Kang HJ, Consortium for Improving Survival of Lymphoma (CISL) investigators, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48:3223–3231.
  • Foss FM, Sjak-Shie N, Goy A, et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013;54:1373–1379.
  • Kim SJ, Shin DY, Kim JS, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016;27:712–718.
  • d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–3099.
  • Dunleavy K, Pittaluga S, Shovlin M, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101:e27–e29.
  • Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16:541–549.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.